Real-World Efficacy of Midostaurin in Aggressive Systemic Mastocytosis

In April 2017 midostaurin was approved by the US Food and Drug Administration for the treatment of patients with aggressive systemic mastocytosis (ASM). So far, very limited real world data on its efficacy is available. Thirteen patients aged from 48 to 79 years, who received midostaurin in the earl...

Descripción completa

Detalles Bibliográficos
Autores principales: Szudy-Szczyrek, Aneta, Bachanek-Mitura, Oliwia, Gromek, Tomasz, Chromik, Karolina, Mital, Andrzej, Szczyrek, Michał, Krupski, Witold, Szumiło, Justyna, Kanduła, Zuzanna, Helbig, Grzegorz, Hus, Marek
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7961806/
https://www.ncbi.nlm.nih.gov/pubmed/33799933
http://dx.doi.org/10.3390/jcm10051109

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7961806/
https://www.ncbi.nlm.nih.gov/pubmed/33799933
http://dx.doi.org/10.3390/jcm10051109

Ejemplares similares